ArticleFrontiers in public health2026
Impact of the volume-based procurement for intraocular lenses combined with the diagnosis-related group's payment reform on hospitalization costs and expenditure structure among cataract patients: an interrupted time series analysis.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cataract surgery is one of the most resource-intensive procedures in China, with intraocular lens (IOL) costs accounting for a substantial proportion of total hospitalization expenditure. To address persistently high prices of high-value medical consumables, our hospital implemented the Beijing-Tianjin-Hebei "3 + N" regional alliance procurement for IOLs in January 2022, followed by DRG payment reform in January 2024. However, the synergistic effects of these two sequential policies on cataract surgery costs-particularly on both cost levels and expenditure composition-have not been systematically evaluated. Methods: We conducted a retrospective analysis of 8,458 cataract patients who underwent IOL implantation at a tertiary hospital in western China from January 2021 to December 2025. A multiple-phase interrupted time series model was used, with monthly medians of costs and cost proportions as outcomes. Two intervention points were defined: IOL-VBP implementation and DRG payment reform. Results: Immediately after VBP, total hospitalization cost, material cost, and surgical cost dropped significantly, though a rebound followed with total and material costs shifting to a monthly increase. Specifically, the median total hospitalization cost decreased from 27,403.68 CNY before the reform to 7,214.21 CNY after VBP, and further to 5,516.60 CNY after DRG-a cumulative reduction of 79.9%; the median material cost declined from 11,119.44 CNY to 4,382.92 CNY after VBP, and then to 2,741.10 CNY after DRG-a reduction of 75.4%. DRG reversed the rebound: total and material costs declined continuously, and the material cost proportion continued to fall. The surgical cost proportion rose from 27.44% to 35.35%, although the median surgical fee remained unchanged-a denominator effect driven by sharper declines in diagnostic and other cost components. Surgical volume nearly tripled over the study period, yet annual analysis using mean costs revealed that real per-case surgical revenue decreased, indicating that total revenue growth was entirely volume-driven. Conclusion: The VBP-DRG combination effectively contained costs and shifted expenditure structure toward services at the relative level. However, this structural improvement did not translate into higher absolute physician compensation. To address this, future reforms should consider dynamic adjustments of DRG weights and service prices to align cost containment with fair recognition of medical professionals' skills.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.